Last reviewed · How we verify
Chemotherapy - Bevacizumab
Inhibits vascular endothelial growth factor A (VEGF-A)
Inhibits vascular endothelial growth factor A (VEGF-A) Used for Colorectal cancer, Breast cancer, Non-small cell lung cancer.
At a glance
| Generic name | Chemotherapy - Bevacizumab |
|---|---|
| Sponsor | ARCAGY/ GINECO GROUP |
| Drug class | Angiogenesis inhibitor |
| Target | VEGF-A |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Bevacizumab is a recombinant humanized monoclonal antibody that binds to VEGF-A, preventing its interaction with its receptors and thereby inhibiting angiogenesis.
Approved indications
- Colorectal cancer
- Breast cancer
- Non-small cell lung cancer
Common side effects
- Hypertension
- Nausea
- Fatigue
Key clinical trials
- Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) (PHASE3)
- Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer (PHASE3)
- A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer (PHASE2)
- Testing the Addition of Atezolizumab to Combination Chemotherapy or Atezolizumab Alone for Metastatic Colon or Rectal Cancer, the COMMIT Study (PHASE3)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chemotherapy - Bevacizumab CI brief — competitive landscape report
- Chemotherapy - Bevacizumab updates RSS · CI watch RSS
- ARCAGY/ GINECO GROUP portfolio CI